Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several statements about LIPITOR/statins and skeletal muscle risk (myopathy/rhabdomyolysis) and mechanism (HMG-CoA reductase inhibition) are supported by the provided label excerpts. However, multiple claims about boxed-warning content and specific framing (e.g., post-workout soreness, “cramps,” and “more likely after physical activity”) are not supported by the supplied excerpts and/or may not match the label language. Overall alignment is partial.
Category Scores
Accurate Statements
Lipitor (atorvastatin) can cause muscle pain.
Supported by Section 5.1 Skeletal Muscle and Section 17.1 Muscle Pain (advice about risk of myopathy and reporting unexplained muscle pain).
Statins such as Lipitor inhibit the enzyme HMG-CoA reductase, which is responsible for cholesterol production in the liver.
Supported by Section 11 (Atorvastatin is an inhibitor of HMG-CoA reductase) and Section 12.1 Mechanism of Action (HMG-CoA reductase inhibition).
The boxed warning for Lipitor includes rhabdomyolysis (muscle tissue breakdown).
Partially supported: Section 5.1 includes rare cases of rhabdomyolysis; however the provided excerpts do not explicitly show a boxed warning. Evaluation is therefore based only on the supplied text showing rhabdomyolysis risk (not that it is in a boxed warning).
Unsupported Statements
Muscle pain with Lipitor can include post-workout muscle soreness.
The provided label excerpts do not mention “post-workout” or exercise-induced soreness as an example.
Inhibiting HMG-CoA reductase may interfere with muscle cholesterol synthesis, leading to muscle damage and pain.
No provided label excerpt states this proposed causal mechanism (muscle cholesterol synthesis interference) in those terms.
Patients taking statins, including Lipitor, are more likely to experience muscle pain and cramps.
The excerpts advise patients about risk of myopathy and reporting muscle pain, but do not support claims about increased likelihood or inclusion of “cramps.”
Statin-associated muscle pain and cramps may be more likely to occur after physical activity.
The provided label excerpts do not support that muscle pain/cramps are more likely after physical activity. (Section 17.1 mentions risk increases with certain medications and grapefruit juice quantity, not exercise timing.)
Lipitor has a boxed warning about the risk of muscle damage.
The provided excerpts include warnings about skeletal muscle and rhabdomyolysis, but none of the provided label text explicitly identifies a boxed warning or its specific contents.
Contradictions
Important Omissions
No mention that the label describes rare rhabdomyolysis/myopathy and that therapy may be temporarily withheld or discontinued in patients with acute serious conditions suggestive of myopathy (Section 5.1), or guidance to report unexplained muscle pain (Section 17.1).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Most risk-related statements are broadly consistent with labeling that advises reporting unexplained muscle pain and describes rhabdomyolysis/myopathy risk. However, unsupported specifics (post-workout soreness; exercise timing; cramps; causal pathway wording) could mislead about the circumstances and symptoms most emphasized by the label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Unsupported specificity regarding exercise/post-workout timing and inclusion of “cramps,” and the label-excerpt set does not explicitly establish the presence/content of a boxed warning for muscle damage.
Suggested Improvement
Rephrase to match provided label excerpts more closely (e.g., report unexplained muscle pain; label discusses myopathy and rare rhabdomyolysis) and avoid asserting boxed-warning status or exercise-triggered timing unless explicitly present in the provided labeling text.